120.22 0.00 (0.00%)
After hours: 4:11PM EDT
|Bid||120.28 x 800|
|Ask||120.37 x 800|
|Day's Range||119.08 - 122.88|
|52 Week Range||72.14 - 128.29|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||65.95|
|Earnings Date||Jul 27, 2020 - Jul 31, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 29, 1995|
|1y Target Est||118.05|
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, June 2, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
How far off is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) from its intrinsic value? Using the most recent financial...
Several top health care stocks are in buy zones or setting up, including Teladoc and Neurocrine Biosciences. They are all worth adding to your watchlist.
Neurocrine Biosciences, cleared a consolidation. NBIX recently reported strong earnings. Biotech makes a drug to treat side effect of some anti-psychotic medications.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the RBC Capital Markets 2020 Global Healthcare Conference at 3:40 p.m. ET on Tuesday, May 19, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
Neurocrine Biosciences (NASDAQ: NBIX) had a big day Tuesday, the latest in a string of good days. Net income hit $37.4 million, and the company's cash grew to more than $1 billion. Neurocrine also doubled its number of patients over the same quarter a year ago.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that multiple scientific presentations and abstracts from its movement disorder programs will be available on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights Platform beginning May 18, 2020. Online recorded data presentations and several posters of INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD) and ONGENTYS® (opicapone) capsules as an add-on treatment for patients with Parkinson's disease, were selected for the online 2020 AAN Science Highlights Platform which replaced the AAN 72nd annual meeting previously scheduled for April 25–May 1. The abstracts were also published in the online supplement to Neurology.
One thing nearly everyone can agree on about the past decade is that it has been very, very good for stock market investors. The Russell 1000 large-company index, which tracks the 1,000 biggest U.S. stocks by market value, has gained roughly 252% since the start of the 2010s, including reinvested dividends.Some stocks have done far better. Microsoft (MSFT) awoke from its long slumber and jumped 545% over the past decade. Dollar General (DG) made a lot of bucks, gaining 632%. And Ulta Beauty (ULTA) has made a lovely 1,325% gain.But those aren't the tippy-top stocks of the Russell 1000. Not even close.Here are the top 10 large-company stocks of the decade, as well as a look at what put them on top of the heap. We chose the Russell 1000 because it offers an even broader look at the stock market than the S&P; 500, but still excludes smaller companies where extremely outsize gains are more common and can more easily come from a single, quick driver. SEE ALSO: The 20 Best Stocks to Buy for 2020
Neurocrine Biosciences, featured in IBD 50 Stocks To Watch, is approaching a buy point as it tackles neurological diseases and disorders.
Neurocrine Biosciences is the IBD Stock Of The Day as shares consolidate following the biotech company's strong first-quarter report. Ingrezza sales held up better than expected.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Idorsia Ltd (SIX: IDIA) today announced, following Investigational New Drug (IND) application acceptance by the U.S. Food and Drug Administration (FDA), Neurocrine Biosciences has exercised its option to license the global rights of Idorsia's ACT-709478. Neurocrine Biosciences plans to initiate a Phase II study with this potent, selective, orally-active and brain penetrating T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new data from RE-KINECT, the largest ever real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (TD) demonstrating that the involuntary movements associated with TD can reduce health-related quality of life in patients living with psychiatric disorders.1 Based on clinical assessments, 28% of the 739 patients in this study had clinician-confirmed possible TD and 75% of patients in this group affirmed that they have felt self-conscious or embarrassed about involuntary movements that they could not seem to control.1 In addition, more than 40% of patients with possible TD reported that involuntary movements had "some" or "a lot" of impact on their ability to continue usual activities, such as talking, socializing and being productive.1 These data were recently published in the Journal of Clinical Psychopharmacology and demonstrate the importance of raising awareness of tardive dyskinesia and its impact on patients, especially during Mental Health Month and Tardive Dyskinesia Awareness Week (May 3–9).
Neurocrine (NBIX) delivered earnings and revenue surprises of 46.43% and 8.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2020 and provided revised full-year 2020 financial expense guidance.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday, May 12, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
Neurocrine Biosciences (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine was cleared by the FDA to market its Parkinson's treatment Ongentys, which it says helps curb muscle stiffness, tremors and slow movement.
Shares of Neurocrine Biosciences Inc. gained 2.8% in trading on Monday after the company said the Food and Drug Administration had approved its Parkinson's disease drug Ongentys. The daily oral treatment can be used as an add-on treatment to levodopa and carbidopa to treat what are called "off" episodes in these patients. "Off" episodes can include muscle stiffness, tremors or slow movement. Clinical trials indicated that the drug reduced the "off" time associated with Parkinson's. The company said it expects to launch Ongentys later this year, citing the COVID-19 pandemic. A spokesperson said the company is not disclosing wholesale acquisition price. Since the start of the year, Neurocrine's stock is down 6.0%. The S&P 500 , in comparison, has tumbled 12.2%.
The U.S. Food and Drug Administration approved Neurocrine Biosciences Inc's add-on treatment for patients with Parkinson's disease, the company said on Monday. The therapy, Ongentys, helps prolong the effect of the drug levodopa, the standard of care for the disorder. The neurodegenerative disease, which causes patients to experience tremors, impaired balance, and difficulties in swallowing and speaking, affects about a million Americans, according to the Parkinson's Disease Foundation.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral ONGENTYS® (opicapone) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes. As the disease progresses, patients taking levodopa/carbidopa may begin to experience "off" time between treatment doses, during which an increase in Parkinson's disease motor symptoms such as tremor, slowed movement and difficulty walking occur. ONGENTYS also increases "on" time without troublesome dyskinesia, the time when the motor symptoms of a patient with Parkinson's disease are better controlled. The company plans to launch ONGENTYS later this year.
It's pretty hard to ignore the impact of Covid-19 on the global and domestic economy. But the shutdown in the U.S. economy, while swift, was also swiftly managed by the administration and Congress, as well as the Federal Reserve. This has helped buoy the markets after a precipitous initial drop. And it has allowed enough time for investors to process everything that has happened and reset their expectations -- looking away from certain risks and into cleaning-supply companies and biotech stocks.Previous to Covid-19, there was the feeling the economy was nearing recession sometime this year. Now we're in one.However, this remains an uneven market. Big stocks like Amazon (NASDAQ:AMZN) and Netflix (NASDAQ:NFLX) are doing even better under these difficult conditions. But other consumer stocks aren't.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat's why I wanted to talk about an opportunity that doesn't have to do with consumer-driven stocks -- the seven beautiful biotech stocks to buy here. These companies are set up to endure long drug approval processes that happen over good times and bad. * CRISPR Therapeutics (NASDAQ:CRSP) * Acceleron Pharma (NASDAQ:XLRN) * Neurocrine Biosciences (NASDAQ:NBIX) * Galapagos NV (NASDAQ:GLPG) * Incyte Corp (NASDAQ:INCY) * Regeneron Pharmaceuticals (NASDAQ:REGN) * Gilead Sciences (NASDAQ:GILD)They're built to be immune from general market forces, especially the big one these days -- consumer spending -- and to benefit from powerful technology that's popping up in all kinds of industries. Biotech Stocks to Buy: CRISPR Therapeutics (CRSP)Source: Catalin Rusnac/ShutterStock.com CRISPR is a Swiss biotech that is one of the leaders in CRISPR technology. This is a new and fast-growing field. CRISPR (it stands for clustered regularly interspaced short palindromic repeats) is a DNA segment containing short repetitions of base sequences.By using these, scientists are learning to identify where there is a break in the pattern that may signal a disease and then repair (or edit) that sequence. This is a revolutionary concept in treating disease, since it is the first step toward personalized medicine.Currently the research is hoping to build treatments to help battle many different cancers and other diseases. But eventually the technology can be applied to a much broader field of needs.The company is well funded and will continue to make a difference, even sequencing Covid-19.The stock is up 37% in the past year and over 30% in the past month. Acceleron Pharma (XLRN)Source: Pavel Kapysh / Shutterstock.com Acceleron is a biopharmaceutical company that has been around since 2003. Last year was a wild ride for the firm, and the volatility continued into 2020.In September, one of its drugs in trials was rejected by the FDA and the stock tanked. Then, shortly after that, its drug luspatercept, which treats a rare blood disorder, was approved.And then, in late January, data from a Phase 2 trial of another drug it has in the approval process for pulmonary arterial hypertension (PAH), showed significant positive results in treating the disorder. This is the kind of situation that can attract big buying pressure on Wall Street of the kind I want to see in Growth Investor.Needless to say, the stock is now up 134% in the past year, and 38% in the past month.One of its largest shareholders is Bristol Myers Squibb (NYSE:BMY). Acceleron had been doing a lot of work with Celgene when BMY bought Celgene. This is a great partnership to have when looking to market, manufacture and distribute these new drugs. Neurocrine Biosciences (NBIX)Source: Shutterstock Neurocrine Biosciences has been in business for over 25 years and specializes in developing treatments for people suffering with neurological, endocrine and psychological disorders.It currently has treatments for tardive dyskinesia and endometriosis. It has candidates for Parkinson's, uterine fibroids and congenital adrenal hyperplasia. Last year, there was talk that Biogen (NASDAQ:BIIB) may have been looking at NBIX as an acquisition to build on its own work in some of these sectors.It's a solid company that has a good balance of revenue-generating drugs and a solid, focused drug pipeline. Neurocrine has a unique niche and will remain an attractive takeover target for larger pharmaceutical companies and biotechs.The stock is up 17% for the past year, and 20% in the past month. Galapagos NV (GLPG)Source: Jarretera / Shutterstock.com Galapagos is a Belgian company that specializes in small molecule and antibody therapies.It was a solid performer and has been around for over 20 years. But its big break happened last year when Gilead approached the company and offered it a $5 billion partnership deal. This brought the stock to the attention of many U.S. investors who hadn't paid much attention to it.And by December, that partnership paid off. GILD filed with FDA for speedy review of filgotinib, a potential blockbuster drug that GLPG developed and had in Europe in Japan but not the U.S. The U.S. is the market where the money is made, since pricing is far more dynamic than in other countries.The approval came in December. And this could mean big things for both companies. But since then, Covid-19 has taken the spotlight and Gilead's remdesivir has been all the buzz.GLPG stock is up over 80% in the past 12 months, and almost 45% in the past month. Its management has also been wise enough to partner with a genomics company that provides what's sometimes nicknamed "the mother of all technologies" to help discover new treatments and drug combinations. Incyte Corp (INCY)Source: Eyesonmilan / Shutterstock.com Incyte has been around since the early 1990s and is good-sized biopharmaceutical company with a $21 billion market capitalization.Currently it has two drugs in the marketplace, one of those is in the US. Its big drug is Jakafi (ruxolitinib), which treats a rare form of blood cancer and is also approved to manage acute graft-versus-host disease in adults.It also has a drug that it acquired from ARIAD Pharmaceuticals for European distribution. Its Iclusig (ponatinib) is used to treat leukemia, and INCY stock hopes to make the drug available in the U.S. after approval from the FDA.Incyte also has a good number of drugs in the pipeline and has the financial wherewithal to keep moving them forward, even now.The stock is up 36% in the past 12 months, and over 60% in the past month. Regeneron Pharmaceuticals (REGN)Source: madamF / Shutterstock.com Regeneron is one of those biotech stocks that has been a direct Covid-19 beneficiary.It has a number of drugs in the market and around 30 drugs in its pipeline. It has been around since 1988 and has a $62 billion market cap, so this is no one-trick pony rolling the dice on a potential blockbuster. It has built its reputation over time, delivering solid drugs in important sectors.But the added juice at this point is its arthritis drug Kevzara that it co-markets with Sanofi (NASDAQ:SNY). It has been given to patients in China and New York (the co-founder of Regeneron is from Queens) but the testing isn't broad enough to deliver any conclusive information.Obviously, the bet on Kevzara being a treatment is just that, a bet. But it has brought more attention to REGN, which is a quality pharma. And Regeneron also has its eye on the big picture of next-generation technology to supercharge its genomics research at the Regeneron Genetics Center.The stock is up almost 62% in the past year and up 22% in the past month. Gilead Sciences (GILD)Source: Michael Moloney / Shutterstock.com Gilead has been a big name among biotech stocks for a long time. It was a key player in finding a treatment for HIV/AIDS. And was also a pioneer in finding a highly effective once-a-day regimen for hepatitis C.While it still makes a good amount of money from these blockbusters, it hadn't had a big hit in a while and the stock flat-lined as investors wondered if its best days were behind it.But it has made some interesting acquisitions and partnerships in the past couple years, one of those being with Galapagos.And now, remdesivir is in two Phase 3 clinical trials as a treatment for Covid-19. This, along with the promising partnership with GLPG stock that's already delivering results, promises that GILD could beback in the running with two potential blockbusters. Even one would be great news.The stock is on the move, up 30% in the past 12 months, and 13% in the past month. And it is still off its 2015 highs, so there's plenty of headroom if either - or both - these drug live up to their promise.Gilead is one of the "big kahunas" in this space, and now a household name, thanks to the fight against Covid-19. It, too, is partnering with smaller labs to harness the power of the game-changing technology of our time: artificial intelligence (AI). The AI Master KeyIf artificial intelligence sounds futuristic, even far-fetched -- well, keep in mind, you're already using it every day. If you've ever used Alphabet's (NASDAQ:GOOG, NASDAQ:GOOGL) Google Assistant or Apple's (NASDAQ:AAPL) Siri … if you've had Netflix (NASDAQ:NFLX) recommend a movie or Zillow (NASDAQ:Z) recommend a house … even an email spam filter … then you've used artificial intelligence.In this new world of AI everywhere, data becomes a hot commodity.As scientists find even more applications for artificial intelligence -- from hospitals to retail to self-driving cars -- it's incredible to imagine how much data will be involved.To create AI programs in the first place, tech companies must collect vast amounts of data on human decisions. Data is what powers every AI system. As one AI researcher from the University of South Florida puts it, "data is the new oil."To cash in, you'll want the company that makes the "brain" that all AI software needs to function, spot patterns and interpret data.It's known as the "Volta Chip" -- and it's what makes the AI revolution possible.You don't need to be an AI expert to take part. I'll tell you everything you need to know, as well as my buy recommendation, in my special report for Growth Investor, The A.I. Master Key. The stock is still under my buy limit price -- so you'll want to sign up now. That way, you can get in while you can still do so cheaply.Click here for a free briefing on this groundbreaking innovation.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * America's 1 Stock Picker Reveals Next 1,000% Winner * 25 Stocks You Should Sell Immediately * 1 Under-the-Radar 5G Stock to Buy Now * The 1 Stock All Retirees Must Own The post 7 Beautiful Biotech Stocks to Buy Here appeared first on InvestorPlace.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...